Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias.
Haloperidol was used in 12 patients in an attempt to improve l-dopa induced dyskinesias. In eight patients any improvement in dyskinesias was associated with increased Parkinsonism. In four patients the dyskinesias initially improved without clinical deterioration. Within several weeks, however, the disability due to Parkinsonism increased in these four patients as well. These observations suggest that long term haloperidol does not effectively decrease l-dopa induced dyskinesias without worsening Parkinsonism.
D000328:Adult; D000368:Aged; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D004359:Drug Therapy, Combination; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced* / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy*
D004295:Dihydroxyphenylalanine; D006220:Haloperidol